Cholinergic modulation of MEG resting-state oscillatory activity in Parkinson's disease related dementia

Clinical Neurophysiology

Volumn 120, Issue 5, 2009, Pages 910-915

  Bosboom, J L W ^a   Stoffers, D ^a,b   Stam, C J ^a   Berendse, H W ^a   Wolters, E Ch ^a  

^a VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^b VU UNIVERSITY AMSTERDAM   (Netherlands)

Author keywords

Cholinesterase inhibitor; Dementia; Frequency analysis; Magneto encephalography (MEG); Parkinson's disease; Resting state; Rivastigmine

Indexed keywords

DECARBOXYLASE INHIBITOR; DOPAMINE RECEPTOR STIMULATING AGENT; LEVODOPA; RIVASTIGMINE;

AGED; ALPHA RHYTHM; ARTICLE; BETA RHYTHM; CHOLINERGIC ACTIVITY; CHOLINERGIC STIMULATION; CLINICAL ARTICLE; CONTROLLED STUDY; DELTA RHYTHM; DRUG WITHDRAWAL; FRONTAL CORTEX; GAMMA RHYTHM; HUMAN; MAGNETOENCEPHALOGRAPHY; NAUSEA; OCCIPITAL LOBE; OSCILLATORY POTENTIAL; PARIETAL LOBE; PARKINSON DISEASE; PRIORITY JOURNAL; STEADY STATE; TEMPORAL LOBE; THETA RHYTHM;

ACETYLCHOLINE; AGED; AGED, 80 AND OVER; BIOLOGICAL CLOCKS; BRAIN MAPPING; CEREBRAL CORTEX; CHOLINESTERASE INHIBITORS; EVOKED POTENTIALS; HUMANS; LEWY BODY DISEASE; MAGNETOENCEPHALOGRAPHY; PHENYLCARBAMATES; SIGNAL PROCESSING, COMPUTER-ASSISTED; SYNAPTIC TRANSMISSION; TREATMENT OUTCOME;

EID: 67349113893     PISSN: 13882457     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.clinph.2009.03.004     Document Type: Article

References (49)

1. Adler G., and Brassen S. Short-term rivastigmine treatment reduces EEG slow-wave power in Alzheimer patients. Neuropsychobiology 43 (2001) 273-276
2. Adler G., Brassen S., Chwalek K., Dieter B., and Teufel M. Prediction of treatment response to rivastigmine in Alzheimer's dementia. J Neurol Neurosurg Psychiatry 75 (2004) 292-294
3. Alhainen K., Partanen J., Reinikainen K., Laulumaa V., Soininen H., Airaksinen M., et al. Discrimination of tetrahydroaminoacridine responders by a single dose pharmaco-EEG in patients with Alzheimer's disease. Neurosci Lett 127 (1991) 113-116
4. Alhainen K., and Riekkinen Sr. P.J. Discrimination of Alzheimer patients responding to cholinesterase inhibitor therapy. Acta Neurol Scand Suppl 149 (1993) 16-21
5. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders. Washington (DC): American Psychiatric Association; 1994.
6. Babiloni C., Cassetta E., Dal Forno G., Del Percio C., Ferreri F., Ferri R., et al. Donepezil effects on sources of cortical rhythms in mild Alzheimer's disease: Responders vs. Non-Responders. Neuroimage 31 (2006) 1650-1665
7. Birks J. Cholinesterase inhibitors for Alzheimer's disease. Cochrane Database Syst Rev 1 (2006) CD005593
8. Bosboom J.L., Stoffers D., Stam C.J., van Dijk B.W., Verbunt J., Berendse H.W., et al. Resting state oscillatory brain dynamics in Parkinson's disease: an MEG study. Clin Neurophysiol 117 (2006) 2521-2531
9. Bosboom J.L., Stoffers D., and Wolters E.C. Cognitive dysfunction and dementia in Parkinson's disease. J Neural Transm 111 (2004) 1303-1315
10. Brassen S., and Adler G. Short-term effects of acetylcholinesterase inhibitor treatment on EEG and memory performance in Alzheimer patients: an open, controlled trial. Pharmacopsychiatry 36 (2003) 304-308
11. Bullock R., and Cameron A. Rivastigmine for the treatment of dementia and visual hallucinations associated with Parkinson's disease: a case series. Curr Med Res Opin 18 (2002) 258-264
12. Burn D., Emre M., McKeith I., De Deyn P.P., Aarsland D., Hsu C., et al. Effects of rivastigmine in patients with and without visual hallucinations in dementia associated with Parkinson's disease. Mov Disord 21 (2006) 1899-1907
13. Buter T.C., van den H.A., Matthews F.E., Larsen J.P., Brayne C., and Aarsland D. Dementia and survival in Parkinson disease: a 12-year population study. Neurology 70 (2008) 1017-1022
14. Buzsaki G., Bickford R.G., Ponomareff G., Thal L.J., Mandel R., and Gage F.H. Nucleus basalis and thalamic control of neocortical activity in the freely moving rat. J Neurosci 8 (1988) 4007-4026
15. Detari L., and Vanderwolf C.H. Activity of identified cortically projecting and other basal forebrain neurones during large slow waves and cortical activation in anaesthetized rats. Brain Res 437 (1987) 1-8
16. Dringenberg H.C., Diavolitsis P., and Noseworthy P.A. Effect of tacrine on EEG slowing in the rat: enhancement by concurrent monoamine therapy. Neurobiol Aging 21 (2000) 135-143
17. Ebert U., and Kirch W. Scopolamine model of dementia: electroencephalogram findings and cognitive performance. Eur J Clin Invest 28 (1998) 944-949
18. Emre M., Aarsland D., Albanese A., Byrne E.J., Deuschl G., De Deyn P.P., et al. Rivastigmine for dementia associated with Parkinson's disease. N Engl J Med 351 (2004) 2509-2518
19. Emre M., Aarsland D., Brown R., Burn D.J., Duyckaerts C., Mizuno Y., et al. Clinical diagnostic criteria for dementia associated with Parkinson's disease. Mov Disord 22 (2007) 1689-1707
20. Fahn S., Elthon R.L., and and members of the UPDRS Development Committee. The unified Parkinson's disease rating scale. Recent developments in Parkinson's disease vol. 2 (1987), Macmillan Healthcare Information, Florham Park, NY 153-163
21. Fogelson N., Kogan E., Korczyn A.D., Giladi N., Shabtai H., and Neufeld M.Y. Effects of rivastigmine on the quantitative EEG in demented Parkinsonian patients. Acta Neurol Scand 107 (2003) 252-255
22. Folstein M.F., Folstein S.E., and McHugh P.R. Mini-mental state. a practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 12 (1975) 189-198
23. Gagnon J.F., Fantini M.L., Bedard M.A., Petit D., Carrier J., Rompre S., et al. Association between waking EEG slowing and REM sleep behavior disorder in PD without dementia. Neurology 62 (2004) 401-406
24. Gianotti L.R., Kunig G., Faber P.L., Lehmann D., Pascual-Marqui R.D., Kochi K., et al. Rivastigmine effects on EEG spectra and three-dimensional LORETA functional imaging in Alzheimer's disease. Psychopharmacology (Berl) 198 (2008) 323-332
25. Gibb W.R. Accuracy in the clinical diagnosis of parkinsonian syndromes. Postgrad Med J 64 (1988) 345-351
26. Green J., and Haycook W.M. Electroencephalographic changes in Parkinsonian patients treated wit levo dopa and levo dopa-amantadine in combination. Clin Electroencephalogr 2 (1971) 28-34
27. Gustafson L., Edvinsson L., Dahlgren N., Hagberg B., Risberg J., Rosen I., et al. Intravenous physostigmine treatment of Alzheimer's disease evaluated by psychometric testing, regional cerebral blood flow (rCBF) measurement, and EEG. Psychopharmacology (Berl) 93 (1987) 31-35
28. Hoehn M.M., and Yahr M.D. Parkinsonism: onset, progression and mortality. Neurology 17 (1967) 427-442
29. Jankovic J., McDermott M., Carter J., Gauthier S., Goetz C., Golbe L., et al. Variable expression of Parkinson's disease: a base-line analysis of the DATATOP cohort. The Parkinson Study Group. Neurology 40 (1990) 1529-1534
30. Jelic V., Dierks T., Amberla K., Almkvist O., Winblad B., and Nordberg A. Longitudinal changes in quantitative EEG during long-term tacrine treatment of patients with Alzheimer's disease. Neurosci Lett 254 (1998) 85-88
31. Jeong J. EEG dynamics in patients with Alzheimer's disease. Clin Neurophysiol 115 (2004) 1490-1505
32. Kikuchi M., Wada Y., Koshino Y., Nanbu Y., and Hashimoto T. Effects of scopolamine on interhemispheric EEG coherence in healthy subjects: analysis during rest and photic stimulation. Clin Electroencephalogr 31 (2000) 109-115
33. Kogan E.A., Korczyn A.D., Virchovsky R.G., Klimovizky S.S., Treves T.A., and Neufeld M.Y. EEG changes during long-term treatment with donepezil in Alzheimer's disease patients. J Neural Transm 108 (2001) 1167-1173
34. Kropf W., and Kuschinsky K. Electroencephalographic correlates of the sedative effects of dopamine agonists presumably acting on autoreceptors. Neuropharmacology 30 (1991) 953-960
35. Neufeld M.Y., Blumen S., Aitkin I., Parmet Y., and Korczyn A.D. EEG frequency analysis in demented and nondemented parkinsonian patients. Dementia 5 (1994) 23-28
36. Neufeld M.Y., Inzelberg R., and Korczyn A.D. EEG in demented and non-demented parkinsonian patients. Acta Neurol Scand 78 (1988) 1-5
37. Ongini E., and Caporali M.G. Differential effects of dopamine D-1 and D-2 receptor agonists on EEG activity and behaviour in the rabbit. Neuropharmacology 26 (1987) 355-360
38. Osipova D., Ahveninen J., Kaakkola S., Jaaskelainen I.P., Huttunen J., and Pekkonen E. Effects of scopolamine on MEG spectral power and coherence in elderly subjects. Clin Neurophysiol 114 (2003) 1902-1907
39. Ray P.G., and Jackson W.J. Lesions of nucleus basalis alter ChAT activity and EEG in rat frontal neocortex. Electroencephalogr Clin Neurophysiol 79 (1991) 62-68
40. Reading P.J., Luce A.K., and McKeith I.G. Rivastigmine in the treatment of parkinsonian psychosis and cognitive impairment: preliminary findings from an open trial. Mov Disord 16 (2001) 1171-1174
41. Ricceri L., Minghetti L., Moles A., Popoli P., Confaloni A., De S.R., et al. Cognitive and neurological deficits induced by early and prolonged basal forebrain cholinergic hypofunction in rats. Exp Neurol 189 (2004) 162-172
42. Riekkinen Jr. P., Sirvio J., Riekkinen M., and Riekkinen P. EEG changes induced by acute and chronic quisqualic or ibotenic acid nucleus basalis lesions are stabilized by tacridine. Brain Res 559 (1991) 304-308
43. Roth M., Tym E., Mountjoy C.Q., Huppert F.A., Hendrie H., Verma S., et al. CAMDEX. A standardised instrument for the diagnosis of mental disorder in the elderly with special reference to the early detection of dementia. Br J Psychiatry 149 (1986) 698-709
44. Rowan E., McKeith I.G., Saxby B.K., O'Brien J.T., Burn D., Mosimann U., et al. Effects of donepezil on central processing speed and attentional measures in Parkinson's disease with dementia and dementia with Lewy bodies. Dement Geriatr Cogn Disord 23 (2007) 161-167
45. Sinanovic O., Kapidzic A., Kovacevic L., Hudic J., and Smajlovic D. EEG frequency and cognitive dysfunction in patients with Parkinson's disease. Med Arh 59 (2005) 286-287
46. Soikkeli R., Partanen J., Soininen H., Paakkonen A., and Riekkinen Sr. P. Slowing of EEG in Parkinson's disease. Electroencephalogr Clin Neurophysiol 79 (1991) 159-165
47. Stoffers D., Bosboom J.L., Deijen J.B., Wolters E.C., Berendse H.W., and Stam C.J. Slowing of oscillatory brain activity is a stable characteristic of Parkinson's disease without dementia. Brain 130 (2007) 1847-1860
48. Tanaka H., Koenig T., Pascual-Marqui R.D., Hirata K., Kochi K., and Lehmann D. Event-related potential and EEG measures in Parkinson's disease without and with dementia. Dement Geriatr Cogn Disord 11 (2000) 39-45
49. Wesnes K.A., McKeith I., Edgar C., Emre M., and Lane R. Benefits of rivastigmine on attention in dementia associated with Parkinson disease. Neurology 65 (2005) 1654-1656